Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.
|Number of pages
|Oncology (Williston Park, N.Y.)
|Published - Nov 1987
ASJC Scopus subject areas
- Cancer Research